265 related articles for article (PubMed ID: 27893711)
21. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
Zhang X; Pickin KA; Bose R; Jura N; Cole PA; Kuriyan J
Nature; 2007 Nov; 450(7170):741-4. PubMed ID: 18046415
[TBL] [Abstract][Full Text] [Related]
22. Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer.
Yang YC; Pan KF; Lee WJ; Chang JH; Tan P; Gu CC; Chang WM; Yang SF; Hsiao M; Hua KT; Chien MH
Cancer Res; 2020 Aug; 80(16):3292-3304. PubMed ID: 32561533
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor.
Wang Z; Raines LL; Hooy RM; Roberson H; Leahy DJ; Cole PA
ACS Chem Biol; 2013 Nov; 8(11):2372-6. PubMed ID: 24004111
[TBL] [Abstract][Full Text] [Related]
24. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
Wendt MK; Williams WK; Pascuzzi PE; Balanis NG; Schiemann BJ; Carlin CR; Schiemann WP
Neoplasia; 2015 Jan; 17(1):124-33. PubMed ID: 25622905
[TBL] [Abstract][Full Text] [Related]
25. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
26. Exploring the interactions of EGFR with phosphorylated Mig6 by molecular dynamics simulations and MM-PBSA calculations.
Zhang Y; Zheng QC
J Theor Biol; 2018 Jun; 447():118-125. PubMed ID: 29574142
[TBL] [Abstract][Full Text] [Related]
27. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
28. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
29. The Tumor Suppressor MIG6 Controls Mitotic Progression and the G2/M DNA Damage Checkpoint by Stabilizing the WEE1 Kinase.
Sasaki M; Terabayashi T; Weiss SM; Ferby I
Cell Rep; 2018 Jul; 24(5):1278-1289. PubMed ID: 30067982
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells.
Yoon YK; Kim HP; Song SH; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
Cancer Lett; 2012 Mar; 316(1):77-84. PubMed ID: 22082529
[TBL] [Abstract][Full Text] [Related]
31. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
Kinehara Y; Nagatomo I; Koyama S; Ito D; Nojima S; Kurebayashi R; Nakanishi Y; Suga Y; Nishijima-Futami Y; Osa A; Nakatani T; Kato Y; Nishide M; Hayama Y; Higashiguchi M; Morimura O; Miyake K; Kang S; Minami T; Hirata H; Iwahori K; Takimoto T; Takamatsu H; Takeda Y; Hosen N; Hoshino S; Shintani Y; Okumura M; Kumagai T; Nishino K; Imamura F; Nakatsuka SI; Kijima T; Kida H; Kumanogoh A
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568033
[TBL] [Abstract][Full Text] [Related]
32. Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR.
Yu XD; Yang R; Leng CJ
Comput Biol Chem; 2016 Apr; 61():251-7. PubMed ID: 26967626
[TBL] [Abstract][Full Text] [Related]
33. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
34. DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.
Nozaki K; Kagamu H; Shoji S; Igarashi N; Ohtsubo A; Okajima M; Miura S; Watanabe S; Yoshizawa H; Narita I
PLoS One; 2014; 9(10):e111019. PubMed ID: 25343452
[TBL] [Abstract][Full Text] [Related]
35. Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
Wang YC; Wu DW; Wu TC; Wang L; Chen CY; Lee H
Int J Biol Sci; 2018; 14(1):47-56. PubMed ID: 29483824
[TBL] [Abstract][Full Text] [Related]
36. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity.
Anastasi S; Baietti MF; Frosi Y; Alemà S; Segatto O
Oncogene; 2007 Dec; 26(57):7833-46. PubMed ID: 17599051
[TBL] [Abstract][Full Text] [Related]
37. Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling.
Yu JJ; Zhou DD; Cui B; Zhang C; Tan FW; Chang S; Li K; Lv XX; Zhang XW; Shang S; Xiang YJ; Chen F; Yu JM; Liu SS; Wang F; Hu ZW; Hua F
Cancer Lett; 2020 Apr; 474():23-35. PubMed ID: 31931029
[TBL] [Abstract][Full Text] [Related]
38. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
[TBL] [Abstract][Full Text] [Related]
39. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
40. Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas.
Luo SY; Sit KY; Sihoe AD; Suen WS; Au WK; Tang X; Ma ES; Chan WK; Wistuba II; Minna JD; Tsao GS; Lam DC
Lung Cancer; 2014 Aug; 85(2):282-92. PubMed ID: 24976335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]